Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.83 - anthrax lethal factor endopeptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
amp deaminase deficiency
AMPD3 is involved in anthrax LeTx-induced macrophage cell death.
Anemia, Sickle Cell
One-step synthesized silver micro-dendrites used as novel separation mediums and their applications in multi-DNA analysis.
Ankylosis
Generalized ankylosis, a lethal factor occurring in Friesian cattle in New Zealand. II. Its mode of inheritance.
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Anthrax
A "dock and lock" approach to preparation of targeted liposomes.
A "Dock and Lock" Approach to Preparation of Targeted Liposomes.
A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins.
A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
A bacteriophage-based platform for rapid trace detection of proteases.
A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
A d-Amino Acid at the N-Terminus of a Protein Abrogates Its Degradation by the N-End Rule Pathway.
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo.
A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection.
A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates.
A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.
A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen.
A fucoidan-quaternary chitosan nanoparticle adjuvant for anthrax vaccine as an alternative to CpG oligodeoxynucleotides.
A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model.
A high-throughput screening approach to anthrax lethal factor inhibition.
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.
A kinetic analysis of protein transport through the anthrax toxin channel.
A model of anthrax toxin lethal factor bound to protective antigen.
A new role for old ligands: discerning chelators for zinc metalloproteinases.
A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.
A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge.
A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.
A novel pharmacophore model for the design of anthrax lethal factor inhibitors.
A Semi-Synthetic Ion Channel Platform for Detection of Phosphatase and Protease Activity.
A semisynthesis platform for investigating structure-function relationships in the N-terminal domain of the anthrax Lethal Factor.
A serological survey of Bacillus anthracis reveals widespread exposure to the pathogen in free-range and captive lions in Zimbabwe.
A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.
A soluble receptor decoy protects rats against anthrax lethal toxin challenge.
A specific activation of the mitogen-activated protein kinase kinase 1 (MEK1) is required for Golgi fragmentation during mitosis.
A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model.
A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials.
A viral nanoparticle with dual function as an anthrax antitoxin and vaccine.
Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors.
Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry.
Acid-induced unfolding of the amino-terminal domains of the lethal and edema factors of anthrax toxin.
Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.
Activation of NF-?B pathway and TNF-? are involved in the cytotoxicity of anthrax lethal toxin in bovine BoMac macrophages.
Activation of phospholipase C and protein kinase C is required for expression of anthrax lethal toxin cytotoxicity in J774A.1 cells.
Activation of the Nlrp1b inflammasome by reduction of cytosolic ATP.
Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation.
Alkaline earth metals are not required for the restoration of the apoform of anthrax lethal factor to its holoenzyme state.
Amiodarone and bepridil inhibit anthrax toxin entry into host cells.
AMPD3 is involved in anthrax LeTx-induced macrophage cell death.
An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.
An anthrax lethal factor mutant that is defective at causing pyroptosis retains proapoptotic activity.
An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
An anthrax toxin variant with an improved activity in tumor targeting.
An ELISA using a recombinant chimera of protective antigen and lethal factor for serodiagnosis of cutaneous anthrax in India.
An enzymatic electrochemiluminescence assay for the lethal factor of anthrax.
An investigation of the pH dependence of copper-substituted anthrax lethal factor and its mechanistic implications.
Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Analysis of the Errors in the Electrostatically Embedded Many-Body Expansion of the Energy and the Correlation Energy for Zn and Cd Coordination Complexes with Five and Six Ligands and Use of the Analysis to Develop a Generally Successful Fragmentation Strategy.
Anthrax and the inflammasome.
Anthrax biosensor, protective antigen ion channel asymmetric blockade.
Anthrax edema factor, voltage-dependent binding to the protective antigen ion channel and comparison to LF binding.
Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin.
Anthrax lethal and edema toxins fail to directly impair human platelet function.
Anthrax Lethal Factor (LF) Mediated Block of the Anthrax Protective Antigen (PA) Ion Channel: Effect of Ionic Strength and Voltage.
Anthrax Lethal Factor Activates K+ Channels To Induce IL-1{beta} Secretion in Macrophages.
Anthrax lethal factor and edema factor act on conserved targets in Drosophila.
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome.
Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha.
Anthrax lethal factor cleaves mouse nlrp1b in both toxin-sensitive and toxin-resistant macrophages.
Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality.
Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages
Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages.
Anthrax lethal factor inhibition.
Anthrax lethal factor inhibitors as potential countermeasure of the infection.
Anthrax Lethal Factor Investigated by Molecular Simulations.
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.
Anthrax lethal factor proteolysis and inactivation of MAPK kinase.
Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.
Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
Anthrax lethal toxin (LeTx) neutralization by PA domain specific antisera.
Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages.
Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms.
Anthrax lethal toxin and the induction of CD4 T cell immunity.
Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells.
Anthrax lethal toxin co-complexes are stabilized by contacts between adjacent lethal factors.
Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria.
Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling.
Anthrax lethal toxin down-regulates type-IIA secreted phospholipase A(2) expression through MAPK/NF-kappaB inactivation.
Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions.
Anthrax lethal toxin enhances cytokine-induced VCAM-1 expression on human endothelial cells.
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.
Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism.
Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production.
Anthrax lethal toxin impairs CD1d-mediated antigen presentation by targeting the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway.
Anthrax lethal toxin impairs IL-8 expression in epithelial cells through inhibition of histone H3 modification.
Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival.
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Anthrax lethal toxin induced lysosomal membrane permeabilization and cytosolic cathepsin release is Nlrp1b/Nalp1b-dependent.
Anthrax lethal toxin induces acute diastolic dysfunction in rats through disruption of the phospholamban signaling network.
Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature.
Anthrax lethal toxin induces endothelial barrier dysfunction.
Anthrax lethal toxin induces human endothelial cell apoptosis.
Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice.
Anthrax Lethal Toxin Inhibits Growth of and Vascular Endothelial Growth Factor Release from Endothelial Cells Expressing the Human Herpes Virus 8 Viral G Protein Coupled Receptor.
Anthrax lethal toxin inhibits translation of hypoxia-inducible factor 1? and causes decreased tolerance to hypoxic stress.
Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis.
Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation.
Anthrax lethal toxin paralyzes neutrophil actin-based motility.
Anthrax lethal toxin promotes dephosphorylation of TTP and formation of processing bodies.
Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1beta and IL-18.
Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo.
Anthrax lethal toxin suppresses chemokine production in human neutrophil NB-4 cells.
Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.
Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism.
Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages.
Anthrax lethal toxin-induced gene expression changes in mouse lung.
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome.
Anthrax Lethal Toxin-Mediated Disruption of Endothelial VE-Cadherin Is Attenuated by Inhibition of the Rho-Associated Kinase Pathway.
Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response.
Anthrax lethal toxin: a weapon of multisystem destruction.
Anthrax mounts a nuclear attack on glucocorticoid signaling.
Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells.
Anthrax Pathogenesis.
Anthrax protective antigen forms oligomers during intoxication of mammalian cells.
Anthrax protective antigen: efficiency of translocation is independent of the number of ligands bound to the prepore.
Anthrax target in macrophages unveiled.
Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: disulfide-linked epitopes, multiple injections, and role of CD4(+) cells.
Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide.
Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously.
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.
Anthrax toxin fusion proteins for intracellular delivery of macromolecules
Anthrax toxin induces hemolysis: an indirect effect through polymorphonuclear cells.
Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.
Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
Anthrax toxin protective antigen--insights into molecular switching from prepore to pore.
Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis.
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo.
Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.
Anthrax toxin requires ZDHHC5-mediated palmitoylation of its surface-processing host enzymes.
Anthrax toxin translocation complex reveals insight into the lethal factor unfolding and refolding mechanism.
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.
Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake.
Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein.
Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar.
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.
Anthrax toxin-mediated delivery of cholera toxin-A subunit into the cytosol of mammalian cells.
Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.
Anthrax toxin: a tripartite lethal combination.
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.
Anthrax toxin: structures, functions and tumour targeting.
Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst.
Anthrax toxins induce shock in rats by depressed cardiac ventricular function.
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling.
Anthrax X-rayed: new opportunities for biodefence.
Anthrax, MEK and cancer.
Anthrax--an overview.
Anthrax: a motor protein determines anthrax susceptibility.
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
Antibacterial Properties of Visible-Light-Responsive Carbon-Containing Titanium Dioxide Photocatalytic Nanoparticles against Anthrax.
Antibacterial role for natural killer cells in host defense to Bacillus anthracis.
Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
Antibody microarrays for native toxin detection.
Antibody Responses to a Spore Carbohydrate Antigen As a Marker of Non-fatal Inhalation Anthrax in Rhesus Macaques.
Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.
Antidotes to anthrax lethal factor intoxication. Part 2: Structural modifications leading to improved in vivo efficacy.
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.
Antigen delivered by anthrax lethal toxin induces the development of memory CD8+ T cells that can be rapidly boosted and display effector functions.
Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets.
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.
Asp 187 and Phe 190 residues in lethal factor are required for the expression of anthrax lethal toxin activity.
Assembly and disassembly kinetics of anthrax toxin complexes.
Assembly of anthrax toxin pore: Lethal-factor complexes into lipid nanodiscs.
Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid.
Asymmetric Cryo-EM Structure of Anthrax Toxin Protective Antigen Pore with Lethal Factor N-Terminal Domain.
Asymmetric hydrogenation of N-sulfonylated-alpha-dehydroamino acids: toward the synthesis of an anthrax lethal factor inhibitor.
Atomic structure of anthrax protective antigen pore elucidates toxin translocation.
Atomic Structures of Anthrax Prechannel Bound with Full-Length Lethal and Edema Factors.
Atomic structures of anthrax toxin protective antigen channels bound to partially unfolded lethal and edema factors.
ATP Depletion Via Mitochondrial F1F0 Complex by Lethal Factor is an Early Event in B. Anthracis-Induced Sudden Cell Death.
Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome.
Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.
Bacillus anthracis Edema Toxin Impairs Neutrophil Actin-based Motility.
Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.
Bacillus anthracis lethal toxin induces cell-type-specific cytotoxicity in human lung cell lines.
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.
Bacillus anthracis Lethal Toxin Represses MMTV Promoter Activity through Transcription Factors.
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Bacillus anthracis' Lethal Toxin Induces Broad Transcriptional Responses in Human Peripheral Monocytes.
Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses.
Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.
Bidirectional effect of Wnt signaling antagonist DKK1 on the modulation of anthrax toxin uptake.
Binding and cell intoxication studies of anthrax lethal toxin.
Binding of N-terminal fragments of anthrax edema factor (EF(N)) and lethal factor (LF(N)) to the protective antigen pore.
Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells.
Biochip for the Detection of Bacillus anthracis Lethal Factor and Therapeutic Agents against Anthrax Toxins.
Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.
Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin.
BPTES inhibits anthrax lethal toxin-induced inflammatory response.
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Bright fluorescent nucleic acid detection with CRISPR-Cas12a and poly(thymine) templated copper nanoparticles.
C/EBP?-Thr217 Phosphorylation Stimulates Macrophage Inflammasome Activation and Liver Injury.
C/EBPbeta phosphorylation rescues macrophage dysfunction and apoptosis induced by anthrax lethal toxin.
CA-074Me protection against anthrax lethal toxin.
Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1.
Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis.
Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity.
Caspase-1 inflammasomes in infection and inflammation.
Cathepsin B-mediated autophagy flux facilitates the anthrax toxin receptor 2-mediated delivery of anthrax lethal factor into the cytoplasm.
Cationic polyamines inhibit anthrax lethal factor protease.
Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities.
CCT chaperonin complex is required for efficient delivery of anthrax toxin into the cytosol of host cells.
CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
Cellular adaptation to anthrax lethal toxin-induced mitochondrial cholesterol enrichment, hyperpolarization, and reactive oxygen species generation through downregulating MLN64 in macrophages.
Cellular and systemic effects of anthrax lethal toxin and edema toxin.
Certhrax toxin, an anthrax-related ADP-ribosyltransferase from Bacillus cereus.
Characterization of macrophage sensitivity and resistance to anthrax lethal toxin.
Characterization of membrane translocation by anthrax protective antigen.
Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes.
Characterization of Novel Piperidine-Based Inhibitor of Cathepsin B-Dependent Bacterial Toxins and Viruses.
Characterization of Protein-Protein Interfaces through a Protein Contact Network Approach.
Characterization of the human immune response to the UK anthrax vaccine.
Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.
Charge requirements for proton gradient-driven translocation of anthrax toxin.
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis.
Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor.
Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties.
Chloroquine enhances survival in Bacillus anthracis intoxication.
Chloroquine prevents T lymphocyte suppression induced by anthrax lethal toxin.
Cisplatin inhibition of anthrax lethal toxin.
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis.
Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody.
Combating the threat of anthrax: a quantitative structure-activity relationship approach.
Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for Endopeptidase Activity-Based Quantification of Anthrax Lethal Factor in Serum.
Computational insights into the interaction of the anthrax lethal factor with the N-terminal region of its substrates.
Conformational dynamics of the anthrax lethal factor catalytic center.
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.
Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin Induced Vascular Effects In Vivo.
Control of anthrax toxin gene expression by the transition state regulator abrB.
COPI coatomer complex proteins facilitate the translocation of anthrax lethal factor across vesicular membranes in vitro.
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages.
Cross-inhibition between furin and lethal factor inhibitors.
Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin.
Cross-Reactivity of Anthrax and C2 Toxin: Protective Antigen Promotes the Uptake of Botulinum C2I Toxin into Human Endothelial Cells.
Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Cryo-electron microscopy study of bacteriophage T4 displaying anthrax toxin proteins.
Cryo-EM structure of the fully-loaded asymmetric anthrax lethal toxin in its heptameric pre-pore state.
Crystal structure of a complex between anthrax toxin and its host cell receptor.
Crystal structure of the anthrax lethal factor.
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.
Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1.
Crystallographic studies of the anthrax lethal toxin
Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide.
Cys-Cys Cross-Linking Shows Contact between the N-Terminus of Lethal Factor and Phe427 of the Anthrax Toxin Pore.
Cytosolic delivery and characterization of the TcdB glucosylating domain by using a heterologous protein fusion.
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells.
Cytotoxic effects of anthrax lethal toxin on macrophage-like cell line J774A.1.
Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.
Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes.
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Cytotoxicity of the Vibrio vulnificus MARTX toxin Effector DUF5 is linked to the C2A Subdomain.
d-Proline-based peptidomimetic inhibitors of anthrax lethal factor.
Dehydroepiandrosterone and melatonin prevent Bacillus anthracis lethal toxin-induced TNF production in macrophages.
Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment.
Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice.
Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice*
Deletion mutants of protective antigen that inhibit anthrax toxin both in vitro and in vivo.
Delineation of interfaces on human alpha-defensins critical for human adenovirus and human papillomavirus inhibition.
Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol.
Delivery of mirror image polypeptides into cells.
Delivery of Non-Native Cargo into Mammalian Cells Using Anthrax Lethal Toxin.
Delivery of nucleic acid into mammalian cells by anthrax toxin.
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis.
Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection.
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles.
Detection of anthrax toxin genetic sequences by the solid phase oligo-probes.
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays.
Detoxified lethal toxin as a potential mucosal vaccine against anthrax.
Development of a cell-based fluorescence resonance energy transfer reporter for Bacillus anthracis lethal factor protease.
Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
Development of a Comprehensive, Validated Pharmacophore Hypothesis for Anthrax Toxin Lethal Factor (LF) Inhibitors Using Genetic Algorithms, Pareto Scoring, and Structural Biology.
Development of a novel multiepitope chimeric vaccine against anthrax.
Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
Development of high-throughput assay of lethal factor using native substrate.
Differentiation of human monocytic cell lines confers susceptibility to Bacillus anthracis lethal toxin.
Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor.
Discovery and development of anthrax lethal factor metalloproteinase inhibitors.
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Distinct regions of NLRP1B are required to respond to anthrax lethal toxin and metabolic inhibition.
Diverse mechanisms for inflammasome sensing of cytosolic bacteria and bacterial virulence.
Dual effect of synthetic aminoglycosides: antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor.
Effect of anthrax toxin's lethal factor on ion channels formed by the protective antigen.
Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Effect of pH and denaturants on the fold and metal status of anthrax lethal factor.
Effect of pH on stability of anthrax lethal factor: correlation between denaturation and activity.
Effect of pH on the catalytic function and zinc content of native and immobilized anthrax lethal factor.
Effective antiprotease-antibiotic treatment of experimental anthrax.
Effects by anthrax toxins on hematopoiesis: a key role for cytokines as mediators.
Effects of anthrax lethal toxin on human primary keratinocytes.
Effects of dynamin inactivation on pathways of anthrax toxin uptake.
Effects of metalloprotease anthrax lethal factor on its peptide-based inhibitor R9LF-1.
Efficient Neutralization of Anthrax Toxin by Chimpanzee Monoclonal Antibodies against Protective Antigen.
Efficient production and characterization of Bacillus anthracis lethal factor and a novel inactive mutant rLFm-Y236F.
Efficient synthetic inhibitors of anthrax lethal factor.
Electrostatic ratchet in the protective antigen channel promotes anthrax toxin translocation.
Electrostatically Embedded Many-Body Expansion for Neutral and Charged Metalloenzyme Model Systems.
Endocrine perturbation increases susceptibility of mice to anthrax lethal toxin.
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.
Erk1/2 inactivation promotes a rapid redistribution of COP1 and degradation of COP1 substrates.
Erythrocytic mobilization enhanced by the granulocyte colony-stimulating factor is associated with reduced anthrax-lethal-toxin-induced mortality in mice.
Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor.
Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay.
Evidence against a human cell-specific role for LRP6 in anthrax toxin entry.
Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.
Examination of anthrax lethal factor inhibition by siderophores, small hydroxamates, and protamine.
Exceptionally Selective Substrate Targeting by the Metalloprotease Anthrax Lethal Factor.
Exclusion of Kif1c as a candidate gene for anthrax toxin susceptibility.
Expression and purification of anthrax toxin protective antigen from Escherichia coli.
Expression of anthrax lethal factor gene by osmolyte induction.
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
Expression of Nlrp1b inflammasome components in human fibroblasts confers susceptibility to anthrax lethal toxin.
Familial outbreak of agricultural anthrax in an area of northern Italy.
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.
Fluorescence resonance energy transfer studies on anthrax lethal toxin.
Frontline Science: Anthrax lethal toxin-induced, NLRP1-mediated IL-1? release is a neutrophil and PAD4-dependent event.
Full Sequence Amino Acid Scanning of ?-Defensin RTD-1 Yields a Potent Anthrax Lethal Factor Protease Inhibitor.
Functional and Evolutionary Analyses Identify Proteolysis as a General Mechanism for NLRP1 Inflammasome Activation.
Functional characterization of protease-treated Bacillus anthracis protective antigen.
Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes.
Functional determinants of human enteric ?-defensin HD5: crucial role for hydrophobicity at dimer interface.
Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis.
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen.
Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.
Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells.
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Gastric pH and Toxin Factors Modulate Infectivity and Disease Progression After Gastrointestinal Exposure to Bacillus anthracis.
GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis.
Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Generation of mouse polyclonal and human monoclonal antibodies against Bacillus anthracis toxin.
Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.
Genetic, physical, and transcript map of the Ltxs1 region of mouse chromosome 11.
Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering.
GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro.
Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.
HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.
HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages.
Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin.
Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin.
High metal substitution tolerance of anthrax lethal factor and characterization of its active copper-substituted analogue.
High throughput detection of human neutrophil peptides from serum, saliva, and tear by anthrax lethal factor-modified nanoparticles.
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.
High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures.
Highly dynamic metal exchange in anthrax lethal factor involves the occupation of an inhibitory metal binding site.
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin.
Histopathological effects of anthrax lethal factor on rat liver.
HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.
Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences.
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.
Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax.
Humanized {theta}-Defensins (Retrocyclins) Enhance Macrophage Performance and Protect Mice from Experimental Anthrax Infections.
Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen.
Identification and validation of a linear protective neutralizing epitope in the ?-pore domain of alpha toxin.
Identification of a lead small-molecule inhibitor of anthrax lethal toxin by using fluorescence-based high-throughput screening.
Identification of a novel zinc metalloprotease through a global analysis of Clostridium difficile extracellular proteins.
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.
Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.
Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.
Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.
Identification of New Dominant-Negative Mutants of Anthrax Protective Antigen Using Directed Evolution.
Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
Identification of novel anthrax toxin countermeasures using in silico methods.
Identification of novel non-hydroxamate anthrax toxin lethal factor inhibitors by topomeric searching, docking and scoring, and in vitro screening.
Identification of small molecule inhibitors of anthrax lethal factor.
Identification of toxin inhibitors using a magnetic nanosensor-based assay.
Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes.
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
Imaging the Cell Entry of the Anthrax Edema and Lethal toxins with Fluorescent Protein Chimeras.
Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.
Immunization by Application of DNA Vaccine onto a Skin Area Wherein the Hair Follicles Have Been Induced into Anagen-onset Stage.
Immunization studies with attenuated strains of Bacillus anthracis.
Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax.
Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin.
Implication of pH in the catalytic properties of anthrax lethal factor.
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins.
In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.
In-cell production of a genetically-encoded library based on the ?-defensin RTD-1 using a bacterial expression system.
Inactivation of rho GTPases by statins attenuates anthrax lethal toxin activity.
Increased Mitochondrial Activity in Anthrax-Induced Cell Death.
Induction of autophagy by anthrax lethal toxin.
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.
Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Inflammasome Sensor NLRP1 Controls Rat Macrophage Susceptibility to Toxoplasma gondii.
Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment.
Inflammasomes: guardians of cytosolic sanctity.
Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin.
Influence of chemical denaturants on the activity, fold and zinc status of anthrax lethal factor.
Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives.
Inhibition of anthrax lethal factor by ssDNA aptamers.
Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.
Inhibition of anthrax protective antigen outside and inside the cell.
Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis.
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Inhibition of IL-1? Expression by Anthrax Lethal Toxin is Reversed by HDAC8 Inhibition in Murine Macrophages.
Inhibition of interleukin 1? (IL-1?) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages.
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Inhibition of S. aureus alpha-hemolysin and B. anthracis lethal toxin by beta-cyclodextrin derivatives.
Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.
Inhibitors of anthrax lethal factor.
Inhibitors of the Metalloproteinase Anthrax Lethal Factor.
Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation.
Insights into the anthrax lethal factor-substrate interaction and selectivity using docking and molecular dynamics simulations.
Insilico studies on anthrax lethal factor inhibitors: pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer.
Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals.
Integrated microfluidic enzyme reactor mass spectrometry platform for detection of anthrax lethal factor.
Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication.
Interactions of anthrax lethal factor with protective antigen defined by site-directed spin labeling.
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
Intracellular calcium antagonist protects cultured peritoneal macrophages against anthrax lethal toxin-induced cytotoxicity.
Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.
Invariant gly residue is important for ?-defensin folding, dimerization, and function: a case study of the human neutrophil ?-defensin HNP1.
Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.
Involvement of domain II in toxicity of anthrax lethal factor.
Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.
Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis.
Ion Conductance of the Stem of the Anthrax Toxin Channel during Lethal Factor Translocation.
Ion selectivity of the anthrax toxin channel and its effect on protein translocation.
Is new always better than old?: The development of human vaccines for anthrax.
Key tissue targets responsible for anthrax-toxin-induced lethality.
Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor.
Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway.
Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques.
Knock-on effect of anthrax lethal toxin on macrophages potentiates cytotoxicity to endothelial cells.
Label-free dual sensing of DNA molecules using GaN nanowires.
Large-scale structural changes accompany binding of lethal factor to anthrax protective antigen: a cryo-electron microscopic study.
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction.
Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.
Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic Cells.
Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits.
Lethal factor of anthrax toxin binds monomeric form of protective antigen.
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax.
Lethal factor unfolding is the most force-dependent step of anthrax toxin translocation.
Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge.
Lethal toxin actions and their consequences.
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.
Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.
Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells.
Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.
Low molecular weight inhibitors of the protease anthrax lethal factor.
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.
Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11.
Lung epithelial injury by B. anthracis lethal toxin is caused by MKK-dependent loss of cytoskeletal integrity.
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition.
Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.
Mapping the anthrax protective antigen binding site on the lethal and edema factors.
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.
Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.
Mass Spectrometric Detection of Bacterial Protein Toxins and Their Enzymatic Activity.
Mast cell activators: a new class of highly effective vaccine adjuvants.
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin.
Mechanism of Diphtheria Toxin Catalytic Domain Delivery to the Eukaryotic Cell Cytosol and the Cellular Factors that Directly Participate in the Process.
Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor.
Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway.
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.
Mitochondrial Impairment is a Critical Event in Anthrax Lethal Toxin-Induced Cytolysis of Murine Macrophages.
Mitochondrial proteins Bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death.
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides.
MKK signaling and vascularization.
Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer.
Modeling the effects of a Staphylococcal Enterotoxin B (SEB) on the apoptosis pathway.
Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways.
Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease.
Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.
Molecular determinants for a cardiovascular collapse in anthrax.
Monitoring anthrax toxin receptor dissociation from the protective antigen by NMR.
Monitoring endocytic trafficking of anthrax lethal factor by precise and quantitative protein labeling.
Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity.
Multicomponent anthrax toxin display and delivery using bacteriophage T4.
Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.
Murine macrophage transcriptional responses to Bacillus anthracis infection and intoxication.
Mutagenesis by retroviral insertion in chemical mutagen-generated quasi-haploid mammalian cells.
Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin.
MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function.
N-fragment of edema factor as a candidate antigen for immunization against anthrax.
N-terminal degradation activates the NLRP1B inflammasome.
NAD+-Glycohydrolase Promotes Intracellular Survival of Group A Streptococcus.
Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin.
Nanopore biosensor for label-free and real-time detection of anthrax lethal factor.
Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines.
Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Neutralizing antibodies and persistence of immunity following anthrax vaccination.
Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model.
Neutrophil elastase mediates pathogenic effects of anthrax lethal toxin in the murine intestinal tract.
NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.
NLRP1 - One NLR to guard them all.
NMR conformational properties of an Anthrax Lethal Factor domain studied by multiple amino acid-selective labeling.
Non-canonical effects of anthrax toxins on hem atop oiesis: implications for vaccine development.
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats.
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
Novel protein targeted therapy of metastatic melanoma.
Novel repression of the glucocorticoid receptor by anthrax lethal toxin.
Novel role of PKR in inflammasome activation and HMGB1 release.
Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
Observations on experimental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus anthracis.
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.
On the role of macrophages in anthrax.
One-pot synthesis of strongly fluorescent DNA-CuInS2 quantum dots for label-free and ultrasensitive detection of anthrax lethal factor DNA.
One-step synthesized silver micro-dendrites used as novel separation mediums and their applications in multi-DNA analysis.
Oxidized ATP protection against anthrax lethal toxin.
PA63 channel of anthrax toxin: an extended beta-barrel.
Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin.
Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.
Passive vaccination with a human monoclonal antibody: Generation of antibodies and studies for efficacy in Bacillus anthracis infections.
Past, imminent and future human medical countermeasures for anthrax.
Pathogenicity, population genetics and dissemination of Bacillus anthracis.
Pathophysiological manifestations in mice exposed to anthrax lethal toxin.
Peptide- and proton-driven allosteric clamps catalyze anthrax toxin translocation across membranes.
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.
Phenotype based functional gene screening using retrovirus-mediated gene trapping in quasi-haploid RAW 264.7 cells.
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.
Pluronic F127-based systemic vaccine delivery systems.
Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine.
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: Implications for broad anti-tumor efficacy.
Potent inhibitors of anthrax lethal factor from green tea.
Predictive and fluorescent nanosensing experimental methods for evaluating anthrax protective antigen and lethal factor interactions for therapeutic applications.
Preparation and characterization of cobalt-substituted anthrax lethal factor.
Present-day conservative treatment retinopathy of prematurity.
Preventing voltage-dependent gating of anthrax toxin channels using engineered disulfides.
Probing the S2' Subsite of the Anthrax Toxin Lethal Factor Using Novel N-Alkylated Hydroxamates.
Production and purification of Bacillus anthracis protective antigen from Escherichia coli.
Production of biologically active Bacillus anthracis edema factor in Escherichia coli.
Profiling lethal factor interacting proteins from human stomach using T7 phage display screening.
Proteasome activity is required for anthrax lethal toxin to kill macrophages.
Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin.
Proteasomes control caspase-1 activation in anthrax lethal toxin-mediated cell killing.
Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen.
Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores.
Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.
Protective antigen composite nanofibers as a transdermal anthrax vaccine.
Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus.
Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen.
Protein expression pattern of murine macrophages treated with anthrax lethal toxin.
Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity.
Protein translocation through anthrax toxin channels formed in planar lipid bilayers.
Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient.
Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.
Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization.
Proteolytic assay-based screening identifies a potent inhibitor of anthrax lethal factor.
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.
Proteolytic processing of Nlrp1b is required for inflammasome activity.
Proteome analysis of mouse macrophages treated with anthrax lethal toxin.
Proteomic analyses of murine macrophages treated with Bacillus anthracis lethal toxin.
Proteomic analysis of the response of the human neutrophil-like cell line NB-4 after exposure to anthrax lethal toxin.
Proteomics study of anthrax lethal toxin-treated murine macrophages.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
Purification and Biophysical Characterization of the Core Protease Domain of Anthrax Lethal Factor.
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.
Quantitative analysis of the effect of cell type and cellular differentiation on protective antigen binding to human target cells.
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays.
Quickening the pace of anthrax research: three advances point towards possible therapies.
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.
Rapid purification of recombinant anthrax-protective antigen under nondenaturing conditions.
Rapid vascular responses to anthrax lethal toxin in mice containing a segment of chromosome 11 from the CAST/Ei strain on a C57BL/6 genetic background.
Rat survival to anthrax lethal toxin is likely controlled by a single gene.
Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.
Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis.
Recombinant expression of Bacillus anthracis lethal toxin components of Indian isolate in Escherichia coli and determination of its acute toxicity level in mouse model.
Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice.
Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis.
Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity.
Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats.
Residue histidine 669 is essential for the catalytic activity of Bacillus anthracis lethal factor.
Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides.
Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin.
Rhodanine derivatives as selective protease inhibitors against bacterial toxins.
Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways.
Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
Role of furin in delivery of a CTL epitope of an anthrax toxin-fusion protein.
Role of macrophage oxidative burst in the action of anthrax lethal toxin.
Role of N-terminal amino acids in the potency of anthrax lethal factor.
Role of residues constituting the 2beta1 strand of domain II in the biological activity of anthrax protective antigen.
Role of the ? Clamp in the Protein Translocation Mechanism of Anthrax Toxin.
Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay.
Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.
Scalable purification of Bacillus anthracis protective antigen from Escherichia coli.
Screening inhibitors of anthrax lethal factor.
Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities.
Secondary structure of anthrax lethal toxin proteins and their interaction with large unilamellar vesicles: a fourier-transform infrared spectroscopy approach.
Secondary Structure Preferences of the Anthrax Toxin Protective Antigen Translocase.
Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli.
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.
Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
Self-assembled "dock and lock" system for linking payloads to targeting proteins.
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha.
Sequence-specific Nucleic Acid Detection from Binary Pore Conductance Measurement.
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Serology and anthrax in humans, livestock and Etosha National Park wildlife.
Serum protease cleavage of Bacillus anthracis protective antigen.
Single, double and quadruple alanine substitutions at oligomeric interfaces identify hydrophobicity as the key determinant of human neutrophil alpha defensin HNP1 function.
Single-step purification of recombinant anthrax lethal factor from periplasm of Escherichia coli.
Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity.
Small molecule inhibitors of anthrax lethal factor toxin.
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Solid tumor therapy by selectively targeting stromal endothelial cells.
Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
Sometimes it takes two to tango: contributions of dimerization to functions of human ?-defensin HNP1.
Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Statistical analysis, optimization, and prioritization of virtual screening parameters for zinc enzymes including the anthrax toxin lethal factor.
Stop the killer: how to inhibit the anthrax lethal factor metalloprotease.
Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.
Strong Mucosal and Systemic Immunities Induced by Nasal Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome-Protamine-DNA Particles.
Structural analysis of a putative aminoglycoside N-acetyltransferase from Bacillus anthracis.
Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers.
Structural characterization of zinc-bound Zmp1, a zinc-dependent metalloprotease secreted by Clostridium difficile.
Structural determinants for the binding of anthrax lethal factor to oligomeric protective antigen.
Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis.
Structure and function of anthrax toxin.
Structure of anthrax lethal toxin prepore complex suggests a pathway for efficient cell entry.
Structure-Activity Relationship of Semicarbazone EGA Furnishes Photoaffinity Inhibitors of Anthrax Toxin Cellular Entry.
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.
Structure-based design of a heptavalent anthrax toxin inhibitor.
Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis.
Sublethal doses of anthrax lethal toxin on the suppression of macrophage phagocytosis.
Sublethal Doses of Bacillus anthracis Lethal Toxin Inhibit Inflammation with Lipopolysaccharide and Escherichia coli Challenge but Have Opposite Effects on Survival.
Subsite specificity of anthrax lethal factor and its implications for inhibitor development.
Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches.
Substrate specificity of the anthrax lethal factor.
Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested.
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Suppressive effects of anthrax lethal toxin on megakaryopoiesis.
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci.
Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1.
Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato.
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.
Systematic mutational analysis of human neutrophil ?-defensin HNP4.
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Targeted silencing of anthrax toxin receptors protects against anthrax toxins.
Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids.
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion.
Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity.
The 2beta(2)-2beta(3) loop of anthrax protective antigen contains a dominant neutralizing epitope.
The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.
The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
The anthrax vaccine: No new tricks for an old dog.
The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.
The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin.
The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.
The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors.
The cytotoxic effect of anthrax lethal toxin on human lung cells in vitro and the protective action of bovine antibodies to PA and LF.
The Design of Inhibitors for Medicinally Relevant Metalloproteins.
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
The effects of anthrax lethal factor on the macrophage proteome: potential activity on nitric oxide synthases.
The effects of anthrax lethal toxin on host barrier function.
The glucocorticoid receptor: a revisited target for toxins.
The HC fragment of tetanus toxin forms stable, concentration-dependent dimers via an intermolecular disulphide bond.
The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS).
The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).
The host response to anthrax lethal toxin: unexpected observations.
The Impact of Protonation on Early Translocation of Anthrax Lethal Factor: Kinetics from Molecular Dynamics Simulations and Milestoning Theory.
The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody.
The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.
The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal Factor and Edema Factors Are Directed to Non-Cross-Reactive Epitopes.
The Makes Caterpillars Floppy (MCF)-Like Domain of Vibrio vulnificus Induces Mitochondrion-Mediated Apoptosis.
The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited.
The N-end rule ubiquitin ligase UBR2 mediates NLRP1B inflammasome activation by anthrax lethal toxin.
The NLRP1 and CARD8 inflammasomes.
The receptors that mediate the direct lethality of anthrax toxin.
The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on the anthrax lethal toxin tolerance of RAW 264.7 cells.
The roles of anthrax toxin in pathogenesis.
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor.
The structure of Mlc titration factor A (MtfA/YeeI) reveals a prototypical zinc metallopeptidase related to anthrax lethal factor.
The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution.
Thermostabilization of protective antigen--the binding component of anthrax lethal toxin.
Thioamide Hydroxypyrothiones Supersede Amide Hydroxypyrothiones in Potency against Anthrax Lethal Factor.
Three dimensional structure of the anthrax toxin translocon-lethal factor complex by cryo-electron microscopy.
Through the looking glass, mechanistic insights from enantiomeric human defensins.
Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy.
Toxicity of anthrax toxin is influenced by receptor expression.
Toxin Inhibition of Antimicrobial Factors Induced by Bacillus anthracis Peptidoglycan in Human Blood.
Toxin-induced resistance in Bacillus anthracis lethal toxin-treated macrophages.
Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
Transcriptional analysis of the three Nlrp1 paralogs in mice.
Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity.
Translocation of Non-Canonical Polypeptides into Cells Using Protective Antigen.
Trapping a translocating protein within the anthrax toxin channel: implications for the secondary structure of permeating proteins.
Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity.
Trp-26 imparts functional versatility to human {alpha}-defensin HNP1.
Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Ultrafast kinetic DNA hybridization assay based on the visualization of threshold turbidity.
Ultrasensitive detection of botulinum neurotoxins and anthrax lethal factor in biological samples by ALISSA.
Ultrastructural features of lymphocyte suppression induced by anthrax lethal toxin and treated with chloroquine.
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Validated MALDI-TOF-MS method for anthrax lethal factor provides early diagnosis and evaluation of therapeutics.
Validation of the anthrax lethal toxin neutralization assay.
Whole-cell voltage clamp measurements of anthrax toxin pore current.
Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C.
Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors.
Zinc content of the Bacillus anthracis lethal factor.
[Anthrax--the past, present and future]
[Characteristics of the immune response to the lethal toxin of Bacillus anthracis]
[Detection of the functionally active domains in the molecule of the lethal factor of the anthrax exotoxin]
[Expression and analysis of biological activity of the recombination anthrax edema factor]
[Expression and characterization of the recombination anthrax lethal factor]
[Expression of ATR-Fc fusion protein in CHO cells]
[Expression, purification and characterization of the recombinant anthrax protective antigen]
[Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro]
[Postinfection and postvaccinal antianthrax immunity in human subjects]
[Preparation and characterization of monoclonal antibodies to the cholera toxin]
[Production and characteristics of monoclonal antibodies to the diphtheria toxin]
[Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
[The effect of the protective antigen of Bacillus anthracis on the formation of immunity under the action of live anthrax vaccines]
[Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen]
Astrocytoma
Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion.
Bacterial Infections
Cationic polyamines inhibit anthrax lethal factor protease.
Constitutive expression of protective antigen gene of Bacillus anthracis in Escherichia coli.
Inhibition of anthrax lethal factor by ssDNA aptamers.
Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.
Brain Injuries
[Timing in the treatment of multiple injuries]
Breast Neoplasms
Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.
Carcinogenesis
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Cholera
Antibody microarrays for native toxin detection.
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato.
coagulation factor viia deficiency
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Coinfection
Circulating Lymphocyte Subsets Induce Secondary Infection in Acute Pancreatitis.
Colitis-Associated Neoplasms
Platelet Depletion/Transfusion as a Lethal Factor in a Colitis-associated Cancer Mouse Model.
Congenital Abnormalities
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Diphtheria
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
Antibody microarrays for native toxin detection.
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells.
Isolation of the lethal factor of diphtheria toxin by electrophoresis in starch gel.
Mechanism of Diphtheria Toxin Catalytic Domain Delivery to the Eukaryotic Cell Cytosol and the Cellular Factors that Directly Participate in the Process.
Peptide Probes Reveal a Hydrophobic Steric Ratchet in the Anthrax Toxin Protective Antigen Translocase.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
Quantitative immunoassay of biotoxins on hydrogel-based protein microchips.
Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis.
[Production and characteristics of monoclonal antibodies to the diphtheria toxin]
Dystocia
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Factor VII Deficiency
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Glaucoma
[Glaucoma and the lethal factor.]
Glioma
Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.
Hemophilia A
Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.
Hepatitis B
Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice.
Hepatitis C
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.
Hepatitis E
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Hydrocephalus
Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.
Hypotension
Anthrax toxins induce shock in rats by depressed cardiac ventricular function.
Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction.
Infections
AMPD3 is involved in anthrax LeTx-induced macrophage cell death.
An investigation of the pH dependence of copper-substituted anthrax lethal factor and its mechanistic implications.
Anthrax lethal factor inhibitors as potential countermeasure of the infection.
Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells.
Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria.
Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production.
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar.
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling.
Antibody Responses to a Spore Carbohydrate Antigen As a Marker of Non-fatal Inhalation Anthrax in Rhesus Macaques.
Bacillus anthracis' Lethal Toxin Induces Broad Transcriptional Responses in Human Peripheral Monocytes.
Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for Endopeptidase Activity-Based Quantification of Anthrax Lethal Factor in Serum.
Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection.
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin.
Exceptionally Selective Substrate Targeting by the Metalloprotease Anthrax Lethal Factor.
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
Gastric pH and Toxin Factors Modulate Infectivity and Disease Progression After Gastrointestinal Exposure to Bacillus anthracis.
Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax.
Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.
Inhibition of anthrax protective antigen outside and inside the cell.
Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation.
Insilico studies on anthrax lethal factor inhibitors: pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer.
Integrated microfluidic enzyme reactor mass spectrometry platform for detection of anthrax lethal factor.
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Lethal toxin actions and their consequences.
Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.
Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin.
Non-canonical effects of anthrax toxins on hem atop oiesis: implications for vaccine development.
Novel role of PKR in inflammasome activation and HMGB1 release.
Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Rapid vascular responses to anthrax lethal toxin in mice containing a segment of chromosome 11 from the CAST/Ei strain on a C57BL/6 genetic background.
Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Serum protease cleavage of Bacillus anthracis protective antigen.
Small Molecule Inhibitors of Bacillus anthracis Protective Antigen Proteolytic Activation and Oligomerization.
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Subsite specificity of anthrax lethal factor and its implications for inhibitor development.
Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci.
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
The role of extracellular products of Pseudomonas aeruginosa in the pathogenesis of infection; an experimental study employing intraperitoneal diffusion chambers.
The roles of anthrax toxin in pathogenesis.
[Expression of ATR-Fc fusion protein in CHO cells]
Influenza, Human
Role of furin in delivery of a CTL epitope of an anthrax toxin-fusion protein.
Leukemia, Myeloid, Acute
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Lymphoma
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Lymphoma, Large-Cell, Anaplastic
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Mediastinitis
Transesophageal irrigation for the treatment of mediastinitis produced by esophageal rupture.
Melanoma
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Novel protein targeted therapy of metastatic melanoma.
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution.
Meningitis
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Myocardial Infarction
Physical inactivity as a lethal factor in myocardial infarction among men.
Neoplasm Metastasis
Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox.
Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis.
Neoplasms
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anthrax lethal toxin enhances cytokine-induced VCAM-1 expression on human endothelial cells.
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.
Anthrax, MEK and cancer.
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis.
HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
Identification of a six lncRNAs signature as novel diagnostic biomarkers for cervical cancer.
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Pattern of tumor cell spread in tissues and organs as a lethal factor in tumor-bearing animals.
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: Implications for broad anti-tumor efficacy.
Production of recombinant lethal factor of Bacillus anthracis in Bacillus subtilis.
Solid tumor therapy by selectively targeting stromal endothelial cells.
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
[Primary hyperparathyroidism: problems on surgical indication and procedure]
Neuroblastoma
Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
Otorhinolaryngologic Diseases
[Suffocation, an important lethal factor for otorhinolaryngological disease]
Paralysis
Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.
Pseudomonas Infections
The role of extracellular products of Pseudomonas aeruginosa in the pathogenesis of infection; an experimental study employing intraperitoneal diffusion chambers.
Retinal Neovascularization
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Retinopathy of Prematurity
Present-day conservative treatment retinopathy of prematurity.
Salmonella Infections
Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms.
Scoliosis
Aetiology and pathogenesis of congenital torticollis and head scoliosis in the equine foetus.
Sepsis
Paeonol Inhibits Lipopolysaccharide-Induced HMGB1 Translocation from the Nucleus to the Cytoplasm in RAW264.7 Cells.
The hidden mortality in surgically treated necrotizing enterocolitis: fungal sepsis.
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Shock, Septic
Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages.
The role of histamine release in shock.
The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on the anthrax lethal toxin tolerance of RAW 264.7 cells.
Starvation
Phosphate starvation enhances the pathogenesis of Bacillus anthracis.
Tetanus
Antibody microarrays for native toxin detection.
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells.
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Pluronic F127-based systemic vaccine delivery systems.
Quantitative immunoassay of biotoxins on hydrogel-based protein microchips.
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Thyroid Carcinoma, Anaplastic
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Thyroid Neoplasms
[Primary hyperparathyroidism: problems on surgical indication and procedure]
Toxemia
Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar.
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax.
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Tuberculosis
Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response.
Uterine Cervical Neoplasms
Identification of a six lncRNAs signature as novel diagnostic biomarkers for cervical cancer.
Vaccinia
Mast cell activators: a new class of highly effective vaccine adjuvants.
Vasculitis
Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism.
Vesicular Stomatitis
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Virus Diseases
Mast cell activators: a new class of highly effective vaccine adjuvants.
Whooping Cough
Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.